PRAX Stock: Price, Earnings History and SEC Filings
Praxis Precision Medicines, Inc. (PRAX) last traded at $285.93, down 0.93% on the latest session and down 1.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.87 against an analyst estimate of $-3.60, a beat of 20.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PRAX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-2.87 | $-3.60 | +20.28% |
| Mar 2026 | May 7, 2026 | $-3.20 | $-3.58 | +10.61% |
| Dec 2025 | Feb 19, 2026 | $-3.50 | $-3.00 | -16.67% |
| Sep 2025 | Nov 5, 2025 | $-3.36 | $-3.45 | +2.61% |
PRAX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How PRAX reacts to earnings
Across its last 8 earnings releases, PRAX moved 10.1% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +15.95% |
| 2026-05-13 | After close | -0.38% |
| 2026-02-19 | Before open | +0.81% |
| 2026-01-06 | After close | +7.23% |
| 2025-11-05 | Before open | -4.14% |
| 2025-08-04 | Before open | -5.55% |
| 2025-05-02 | Before open | +5.73% |
| 2025-02-28 | Before open | -40.64% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PRAX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $0 | -$303M | -$249M | – | $-13.48 |
| 2024 | $9M | -$183M | -$132M | -2137.5% | $-10.21 |
| 2023 | $2M | -$123M | -$111M | -5037.9% | $-18.69 |
| 2022 | $0 | -$214M | -$185M | – | $-69.65 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PRAX
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jul 7, 2026Other events
- 8-K · Jul 2, 2026Financial statements and exhibits
- 8-K · Jun 29, 2026Other events
- 8-K · Jun 22, 2026Other events
- 8-K · Jun 12, 2026Shareholder vote
- 8-K · Jun 1, 2026Other events
- 8-K · May 7, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 7, 2026
Insider filing activity
PRAX insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PRAX news
- Is Investor Day Plans Altering The Investment Case For Praxis Precision Medicines (PRAX)?Oct 28, 2026 · finance.yahoo.com
- Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference ParticipationOct 27, 2026 · finance.yahoo.com
- Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsightOct 27, 2026 · finance.yahoo.com
- Praxis Precision Medicines, Inc.Oct 23, 2026 · cnn.com
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. (PRAX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.